

**DANCANN PHARMA A/S**<http://www.dancann.com>**Sector: Healthcare**  
**Listing: Spotlight**  
**Market cap: DKK 89,5 million****Latest analysis: [March 24, 2022](#) (justified value per share: DKK 7.6)**

## Strengthens future pipeline by at least SEK 37 million

At the end of 2021, DanCann Pharma reported its first sales revenues of DKK 874,000. For its future sales, DanCann has secured several distribution agreements, including with Tetra BioPharma, which is expected to bring revenue during the current calendar year and which, according to the company, can bring sales up to DKK 340-410 million in 2028.

Yesterday, DanCann Pharma announced that the company has signed a letter of intent with Aureum Pharma with exclusive rights to distribute DanCann Pharma's own produced products from Biotech Pharm1 on the Swedish market. The agreement means that DanCann Pharma and Aureum Pharma aim to enter a binding delivery- and distribution agreement where Aureum Pharma will buy, repackage, market and distribute the products to the Swedish market. The agreement is expected to be implemented in 2023 with a distribution commitment of minimum SEK 37 million over three years.

Carlsquare is very positive about the development towards commercialization DanCann Pharma is showing and that the company continues to strengthen its future pipeline. We await the company's quarterly report, which will be released on May 18, after which we will publish our quarterly update.

Carlsquare published the latest update on DanCann Pharma on March 24, 2022, with a justified value of DKK 7.6. Read the full research update [here](#).

## Disclaimer

Carlsquare AB, [www.carlsquare.se](http://www.carlsquare.se), hereinafter referred to as Carlsquare, conducts business with regard to Corporate Finance and Equity Research in which areas it, among other things, publishes information about companies including analyzes. The information has been compiled from sources that Carlsquare considers to be reliable. However, Carlsquare cannot guarantee the accuracy of the information. Nothing written in the analysis should be regarded as a recommendation or invitation to invest in any financial instrument, option or the like. Opinions and conclusions expressed in the analysis are intended only for the recipient.

The content may not be copied, reproduced or distributed to another person without the written approval of Carlsquare. Carlsquare shall not be held responsible for any direct or indirect damage caused by decisions made on the basis of information contained in this analysis. Investments in financial instruments provide opportunities for value increases and profits. All such investments are also subject to risks. Risks vary between different types of financial instruments and combinations of these. Historical returns should not be considered as an indication of future returns.

The analysis is not directed to U.S. persons (as defined in Regulation S of the United States Securities Act and interpreted in the United States Investment Company Act 1940) nor may it be disseminated to such persons. The analysis is also not directed to such natural and legal persons where the distribution of the analysis to such persons would result in or entail a risk of a violation of Swedish or foreign law or constitution.

The analysis is a so-called Commissioned Research Report where the analysed Company has signed an agreement with Carlsquare for analysis coverage. The analyses are published on an ongoing basis during the contract period and for a usual fixed remuneration.

Carlsquare may or may not have a financial interest in the subject of this analysis. Carlsquare values the assurance of objectivity and independence and has established procedures for managing conflicts of interest for this purpose.

The analysts Fredrik Nilsson and Markus Augustsson do not own and are not allowed to own shares in the company analysed.